| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51d0f239a7f451904cdbd36c61d9e37e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-225 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 |
| filingDate |
1991-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0520d589a99a0727d708878505e4086a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f75878a27ec0e50dbd6d325258a6088 |
| publicationDate |
1992-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0495963-A1 |
| titleOfInvention |
Improved hypoglycemics |
| abstract |
Non-insulin dependent or type 2 diabetes mellitus is treated by the administration of a hypoglycemic agent that stimulates plasma amylin concentrations and an amylin antagonist. The hypoglycemic agent can be a sulfonylurea or a biguanide. The amylin antagonist can be an amylin peptide or a peptide related to a calcitonin gene which has altered reactive sites, which is crosslinked or truncated. In addition, patients are monitored for increased plasma concentrations of amylin following administration of hypoglycemic agents, and the effects of the agents on amylin secretion in a biological system such as culture of an island of beta cells are monitored by analysis. |
| priorityDate |
1990-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |